Prescription medicine
Flurazepam First approved as Dalmane
Flurazepam (Dalmane) is a prescription medicine with an FDA approval on record since 1970. FDA's NDC Directory lists it from 1 generic labeler.
- Generic listed
- In shortage
- Boxed warning
- DEA Schedule IV
Check it at the source: the flurazepam FDA label on DailyMed (effective October 28, 2024, Chartwell RX, LLC); the NDA 16721 record on Drugs@FDA; every flurazepam label on DailyMed.
Highlights of the record
FDA label of October 28, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION.
and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions ( 5.1 ) and Drug Interactions ( 7.1 ) ]. The use of benzodiazepines, including flurazepam hydrochloride capsules, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing flurazepam hydrochloride capsules, and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction [ see Warnings and Precautions ( 5.2 ) ]. The continued use of benzodiazepines, including flurazepam hydrochloride capsules, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. […]
Used for
From the label: indications and usageFlurazepam hydrochloride capsules are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings [see Clinical Studies ( 14 ) ].
Forms and strengths
- 15 mg
- 30 mg
Capsule.
On the market
- Earliest approval on file
- April 7, 1970 Dalmane, Valeant Pharm Intl; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 17 first June 12, 1985; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 1 of which 1 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- 2 of 6 presentations limited or unavailable updated September 15, 2026
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 395 through July 30, 2026
What is flurazepam used for?
From the label: indications and usageFlurazepam hydrochloride capsules are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings [see Clinical Studies ( 14 ) ]. Since insomnia is often transient and intermittent, short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. Flurazepam, a gamma-aminobutyric (GABA A ) agonist, is indicated for the treatment of insomnia characterized by difficulty falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.
Conditions named in the indications of flurazepam's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Benzodiazepine.
Source: FDA drug label (Flurazepam Hydrochloride), Chartwell RX, LLC, effective October 28, 2024 (SPL set 8f476891-1346-4e8c-ac1b-f8cbdc64f5a1), via openFDA; the full label on DailyMed
What does the patient leaflet for flurazepam say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about flurazepam hydrochloride capsules?Flurazepam hydrochloride capsules are a benzodiazepine medicine. Taking benzodiazepines with opioid medicines, alcohol, or other central nervous system (CNS) depressants (including street drugs) can cause severe drowsiness, breathing problems (respiratory depression), coma and death. Get emergency help right away if any of the following happens: shallow or slowed breathing breathing stops (which may lead to the heart stopping) excessive sleepiness (sedation). Do not drive or operate heavy machinery until you know how taking flurazepam hydrochloride capsules with opioids affect you. Risk of abuse, misuse, and addiction. There is a risk of abuse, misuse, and addiction with benzodiazepines, including flurazepam hydrochloride capsules, which can lead to overdose and serious side effects including coma and death. Serious side effects including coma and death have happened in people who have abused or misused benzodiazepines, including flurazepam hydrochloride capsules. These serious side effects may also include delirium, paranoia, suicidal thoughts or actions, seizures, and difficulty breathing. Call your healthcare provider or go to the nearest hospital emergency room right away if you get any of these serious side effects. You can develop an addiction even if you take flurazepam hydrochloride capsules exactly as prescribed by your healthcare provider. Take flurazepam hydrochloride capsules exactly as your healthcare provider prescribed. Do not share your flurazepam hydrochloride capsules with other people. Keep flurazepam hydrochloride capsules in a safe place and away from children. Physical dependence and withdrawal reactions. […]
From the patient leaflet: How should I store flurazepam hydrochloride capsules?Store at 20° to 25°C (68° to 77°F). Keep flurazepam hydrochloride capsules in a tightly closed container and out of the light. Keep flurazepam hydrochloride capsules and all medicines out of the reach of children.
Source: FDA drug label (Flurazepam Hydrochloride), Chartwell RX, LLC, effective October 28, 2024 (SPL set 8f476891-1346-4e8c-ac1b-f8cbdc64f5a1), via openFDA; the full label on DailyMed
Is there a generic for flurazepam (Dalmane)?
The FDA approved the first generic flurazepam on June 12, 1985. 17 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists flurazepam from 1 labeler under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1970 earliest approval on file
- 1985 first generic approved
- 2022 to now in shortage
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Is flurazepam in shortage?
The FDA Drug Shortage Database lists 2 of 6 flurazepam presentations as limited or unavailable (updated September 15, 2026); the first entry was posted on August 3, 2022. 4 more presentations are on the list as available.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01) | Rising Pharma Holdings, Inc. | Current | September 1, 2026 |
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30) | Chartwell Molecular Holdings LLC | Current | September 15, 2026 |
| Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90) | Chartwell Molecular Holdings LLC | Current | September 15, 2026 |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01) | Rising Pharma Holdings, Inc. | Current | September 1, 2026 |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30) | Chartwell Molecular Holdings LLC | Current | September 15, 2026 |
| Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90) | Chartwell Molecular Holdings LLC | Current | September 15, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the flurazepam label say about other medicines?
The flurazepam label names 1 other medicine in its interaction, contraindication or warning sections. The labels of 9 other medicines name flurazepam. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Flumazenil | warnings and precautions | Abrupt discontinuation or rapid dosage reduction of flurazepam hydrochloride capsules after continued use, or administration of flumazenil (a benzodiazepine antagonist) may precipitate acute withdrawal reactions, which can be life-threatening (e.g., seizures) [ see Drug Abuse and Dependence ( 9.3 ) ]. |
Other labels that name flurazepam
Source: FDA drug label (Flurazepam Hydrochloride), Chartwell RX, LLC, effective October 28, 2024 (SPL set 8f476891-1346-4e8c-ac1b-f8cbdc64f5a1), via openFDA; the full label on DailyMed
What do FAERS reports show for flurazepam?
The FDA Adverse Event Reporting System holds 395 reports that list flurazepam among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 43 are coded as a death and 205 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as flurazepam?
11 other medicines are given the same way (oral) and in the same FDA class as flurazepam or labeled mainly for the same use (insomnia), the same class first. Insomnia lists all 14 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Temazepam | Insomnia | 20 labelers | $0.0767 per capsule 15 mg capsule | No current entry |
| Triazolam | Insomnia | 7 labelers | $0.308 per tablet 0.25 mg tablet | No current entry |
| Estazolam | Insomnia | 3 labelers | $0.839 per tablet 2 mg tablet | No current entry |
| Quazepam | Insomnia | none listed | n/a | No current entry |
| Zolpidem | Insomnia | 39 labelers | $0.0344 per tablet 5 mg tablet | No current entry |
| Eszopiclone | Insomnia | 26 labelers | $0.0993 per tablet 1 mg tablet | No current entry |
| Ramelteon | Insomnia | 27 labelers | $0.660 per tablet 8 mg tablet | A presentation being discontinued |
| Zaleplon | Insomnia | 9 labelers | $0.141 per capsule 10 mg capsule | No current entry |
Every medicine labeled for the same conditions as flurazepam
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to flurazepam
- 11 medicines for the same use
- Other benzodiazepines
- the pharmacologic class, with prices and generics
- Flurazepam side effects
- the label's list beside FAERS reports
- Flurazepam shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other